Prospects of antigen-specific therapy in type 1 diabetes mellitus
https://doi.org/10.14341/2072-0351-5534
Abstract
Type 1 diabetes mellitus is commonly recognized as an autoimmune disease characterized by progressive destruction of pancreatic ?-beta-cells. Progress in diagnostics at preclinical stage is accompanied with active development of preventive measures. So far, there are no specific therapeutic agents approved for clinical practice. However, ongoing large-scale studies have outlined some promising solutions, antigen-specific immunotherapy being one of them.
About the Authors
Tatiana Vasil'evna Nikonova
Endocrinology Research Centre
Russian Federation
MD, PhD
Russian Federation
MD, PhD
Yulia Viktorovna Alekseeva
Endocrinology Research Centre
Russian Federation
postgraduate student
Russian Federation
postgraduate student
References
1. Phillips B, Trucco M, Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of thesame? Clin Dev Immunol. 2011;2011:432016. Epub 2011 Jul 18.
2. Nicholas D, Odumosu O, Langridge WH. Autoantigen Based Vaccines for Type 1 Diabetes. Discov Med. 2011 Apr;11(59):293-301.
3. Kuraeva TL, Titovich EV, Peterkova VA. Poslednie dostizheniya i perspektivy profilaktiki sakharnogo diabeta i tipa. Diabetes mellitus. 2000;(1):26-32.
4. Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia. 1998 May;41(5):536-541.
5. Diabetes Prevention Trial--Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346(22):1685-1691.
6. Dosenko JM, Skyler JS, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 2012 Jun;61(6):1331-1337.
7. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, HyötyH,Ilonen J, Veijola R, Simell T, Knip M, Simell O.Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferringincreased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008 Nov 15;372(9651):1746-55. Epub 2008 Sep 22.
8. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, Spera S, Suraci C, Multari G, Cervoni M, MancaBitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 2000 Aug;43(8):1000-1004.
9. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan- Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentrerandomised controlled trial. Diabete Insuline Orale group. Lancet. 2000 Aug 12;356(9229):545-549.
10. www.dvdc.org.au
11. Dedov II, Shestakova MV, Andreeva EN, Belovalova IM, Vikulova OK, Galitsina NA, Galstyan GR, Grigoryan OR, Emel'yanov AO, Zil'berman LI, Kandror VI, Kononenko IV, Kuraeva TL, Mayorov AYu, Maslova OV, Mel'nikova OG, Motovilin OG, Nikitin AG, Nikonova TV, Nosikov VV, Peterkova VA, Seregin YuA, Smirnova OM, Starostina EG, Suntsov YuI, Surkova EV, Sukhareva OYu, Titovich EV, Philippov YuI, Yushkov PV. Diabetes mellitus: diagnosis, treatment, prophylactics. Ed by Dedov II, Shestakova MV. Moskow: MIA; 2011. pp. 290-301.
12. Larsson HE, Lernmark A. Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in thepancreatic islet cells? Hum Vaccin. 2011 Jan 1;7(1):45-49. Epub 2011 Jan 1.
13. www.diamyd.com
14. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, Harris RA, Robertson JA, LernmarkA. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005 Jul-Aug;19(4):238-246.
15. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R.GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-1920. Epub 2008 Oct 8.
16. Horvath L, Cervenak L, Oroszlan M, Prohaszka Z, Uray K, Hudecz F, Baranyi E, Madacsy L, Singh M, Romics L, Fust G, Panczel P. Antibodies against different epitopes of heatshock protein 60 in children with type 1 diabetes mellitus. Immunol Lett. 2002 Mar 1;80(3):155-162.
17. Sobel DO, Creswell K. Characterization of anti-islet cytotoxic human T-cell clones from patients with type 1 diabetes mellitus. Autoimmunity. 2006 Jun;39(4):323-332.
18. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Treatment of new-oncet type 1 diabetes with peptide DiaPep 277 is safe and associated with preserved -cell function: extension of randomized, double-blind phase II trial. Diabetes Metab Res Rev. 2007 May;23(4):292-298.
19. Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep 277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. 2009 May;25(4):316-320.
20. Fischer B, Elias D, Bretzel RG, Linn T. Immunomodulation with heat- shock protein DiaPep 277 to preserve -cell function in type 1 diabetes - an update. Expert Opin Biol Ther. 2010 Feb;10(2):265-272.
21. Huurman VA, Decocher K, Mathieu C, Cohen IR, Roep BO.Therapy with the hsp 60 peptide DiaPep 277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-275.
22. Schlott NC, Meirhoff G, Lenguel C, Vándorfi G, Tacács J, Pánczel P, Barcai L, Madácsy L, Oraszlán T, Kovács P, Su̎ to̎ G, Battelino T, Hosszufalusi N, Jermendy G. Effect of heat shock protein peptide DiaPep 277 on -cell function in paediatric and adult patients with recent-oncet diabetes mellitus type 1: two prospective, randomized double-blind phase II trials. Diabetes Metab Res Rev. 2007 May;23(4):276-285.
23. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. Heat-shock protein peptide DiaPep 277 treatment in children with newly diagnosed type 1 diabetes: a randomized, double-blind phase II study. Diabetes Metab Res Rev. 2007 May;23(4):286-291.
24. Raz I, LinnT, Ziegler A-G, Schernthaner G, Bonnici F, Eren R, Elias D, Dagan S, Ppozzilli P. Resent data from DIA-AID 1, a global phase III clinical study using DiaPep277 for the treatment of newly diagnosed type 1 diabetes patients. Diabetologia. 2012;55(Suppl.1):66.
Review
For citations:
Nikonova T.V., Alekseeva Yu.V. Prospects of antigen-specific therapy in type 1 diabetes mellitus. Diabetes mellitus. 2012;15(4):28-32. (In Russ.) https://doi.org/10.14341/2072-0351-5534
Views:
1330
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
